New TB treatment breakthroughs must reach those in-need without delay
|
Shobha Shukla – CNS
Contd from previous issue
Reduction in dosing and duration of Linezolid means people on this therapy faced less
Linezolid-related side-effects - so treatment becomes more tolerable.
This ZeNix study was led by TB Alliance and took place in eleven sites across Georgia, Moldova, Russia, and South Africa.
Why ZeNix study results are important and build upon the evidence of previously done Nix-TB study?
The Nix-TB Study results, which were published in New England Journal of Medicine in 2020, had
shown very high treatment success rate of
over 90% when all-oral BPaL treatment regimen was used for six months to treat drug-resistant forms of TB.
But the Linezolid-related side effects were very alarming.
(To be contd)
Contd from previous issue
Reduction in dosing and duration of Linezolid means people on this therapy faced less
Linezolid-related side-effects - so treatment becomes more tolerable.
This ZeNix study was led by TB Alliance and took place in eleven sites across Georgia, Moldova, Russia, and South Africa.
Why ZeNix study results are important and build upon the evidence of previously done Nix-TB study?
The Nix-TB Study results, which were published in New England Journal of Medicine in 2020, had
shown very high treatment success rate of
over 90% when all-oral BPaL treatment regimen was used for six months to treat drug-resistant forms of TB.
But the Linezolid-related side effects were very alarming.
(To be contd)